Cantargia builds power

LU Bio has invested SEK 5.8 million in Cantargia and now holds a 52 % stake in the company, with the remainder held by the founders.

Cantargia has recruited Agneta Svedberg as CEO. Agneta most recently held a Senior Advisor position at Semcon. She has extensive experience in antibody drug development having worked for ten years as a member of the R&D management team and lately also in the senior management team at Genmab A/S.

Mats Strömqvist, CEO of Omniohealer AB, serves as Cantargia’s Chairman of the Board. New board member Olof Tydén has clinical and regulatory experience from the international pharmaceutical industry and expertise within hematology.

For more information on Cantargia visit www.cantargia.com.